



## OPEN ACCESS

APPROVED BY  
Frontiers Editorial Office,  
Frontiers Media SA, Switzerland

\*CORRESPONDENCE  
Simon Faissner  
✉ [simon.faissner@rub.de](mailto:simon.faissner@rub.de)

RECEIVED 23 June 2025

ACCEPTED 09 July 2025

PUBLISHED 24 July 2025

## CITATION

Hoffrogge R, Karachunskaya A, Heitmann N, Haupteltshofer S, Pedreiturria X, Klöster K, Bader V, Winklhofer KF, Hamacher M, Klebl B, Gold R, Dinkel K, Kleiter I and Faissner S (2025) Correction: The P2X7R-antagonist AFC-5128 ameliorates chronic experimental autoimmune encephalomyelitis in a preventive and therapeutic paradigm. *Front. Immunol.* 16:1652299. doi: 10.3389/fimmu.2025.1652299

## COPYRIGHT

© 2025 Hoffrogge, Karachunskaya, Heitmann, Haupteltshofer, Pedreiturria, Klöster, Bader, Winklhofer, Hamacher, Klebl, Gold, Dinkel, Kleiter and Faissner. This is an open-access article distributed under the terms of the [Creative Commons Attribution License \(CC BY\)](https://creativecommons.org/licenses/by/4.0/). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

# Correction: The P2X7R-antagonist AFC-5128 ameliorates chronic experimental autoimmune encephalomyelitis in a preventive and therapeutic paradigm

Robert Hoffrogge<sup>1</sup>, Anna Karachunskaya<sup>1</sup>, Neele Heitmann<sup>1</sup>, Steffen Haupteltshofer<sup>2</sup>, Xiomara Pedreiturria<sup>1</sup>, Katharina Klöster<sup>1</sup>, Verian Bader<sup>3</sup>, Konstanze F. Winklhofer<sup>3</sup>, Michael Hamacher<sup>4</sup>, Bert Klebl<sup>5</sup>, Ralf Gold<sup>1</sup>, Klaus Dinkel<sup>6</sup>, Ingo Kleiter<sup>1,7</sup> and Simon Faissner<sup>1\*</sup>

<sup>1</sup>Department of Neurology, St. Josef-Hospital, Bochum, Germany, <sup>2</sup>Translational Neurology Group, Department of Clinical Science, Lund University, Lund, Sweden, <sup>3</sup>Molecular Cell Biology, Ruhr-University, Bochum, Germany, <sup>4</sup>Affectis Pharmaceuticals AG, Dortmund, Germany, <sup>5</sup>KHAN Technology Transfer Fund I GmbH & Co KG, Dortmund, Germany, <sup>6</sup>Lead Discovery Center GmbH, Dortmund, Germany, <sup>7</sup>Behandlungszentrum Kempfenhausen für Multiple Sklerose Kranke gemeinnützige GmbH, Berg, Germany

## KEYWORDS

P2X7R, progressive multiple sclerosis, microglia, neuroinflammation, neuroprotection

## A Correction on

The P2X7R-antagonist AFC-5128 ameliorates chronic experimental autoimmune encephalomyelitis in a preventive and therapeutic paradigm

By Hoffrogge R, Karachunskaya A, Heitmann N, Pedreiturria X, Klöster K, Bader V, Winklhofer KF, Hamacher M, Klebl B, Gold R, Dinkel K, Kleiter I and Faissner S (2025). *Front. Immunol.* 16:1554999. doi: 10.3389/fimmu.2025.1554999

Author “Steffen Haupteltshofer” was omitted as an author in the published article. The correct author list reads:

“Robert Hoffrogge<sup>1</sup>, Anna Karachunskaya<sup>1</sup>, Neele Heitmann<sup>1</sup>, Steffen Haupteltshofer<sup>2</sup>, Xiomara Pedreiturria<sup>1</sup>, Katharina Klöster<sup>1</sup>, Verian Bader<sup>3</sup>, Konstanze F. Winklhofer<sup>3</sup>, Michael Hamacher<sup>4</sup>, Bert Klebl<sup>5</sup>, Ralf Gold<sup>1</sup>, Klaus Dinkel<sup>6</sup>, Ingo Kleiter<sup>1,7</sup>, Simon Faissner<sup>1\*</sup>

<sup>1</sup>Department of Neurology, St. Josef-Hospital, Bochum, Germany

<sup>2</sup>Translational Neurology Group, Department of Clinical Science, Lund University, Lund, Sweden

<sup>3</sup>Molecular Cell Biology, Ruhr-University, Bochum, Germany

<sup>4</sup>Affectis Pharmaceuticals AG, Dortmund, Germany

<sup>5</sup>KHAN Technology Transfer Fund I GmbH & Co KG, Dortmund, Germany

<sup>6</sup>Lead Discovery Center GmbH, Dortmund, Germany

<sup>7</sup>Behandlungszentrum Kempfenhausen für Multiple Sklerose Kranke gemeinnützige GmbH, Berg, Germany”

The **Author contributions statement** has been corrected to read:

“RH: Writing – original draft, Writing – review & editing, Conceptualization, Data curation, Formal Analysis, Investigation, Methodology, Visualization. AK: Writing – review & editing, Formal Analysis, Investigation, Methodology, Visualization. NH: Writing – review & editing, Conceptualization, Data curation, Formal Analysis, Investigation, Methodology, Validation, Visualization. SH: Writing – original draft, Writing – review & editing, Conceptualization, Data curation, Formal Analysis, Investigation, Methodology, Validation, Visualization. XP: Writing – review & editing, Formal Analysis, Investigation, Methodology, Project administration, Resources, Validation. KK: Writing – review & editing, Data curation, Formal Analysis, Investigation, Methodology. VB: Writing – review & editing, Formal Analysis, Investigation, Methodology, Software, Visualization. KW: Writing – review & editing, Formal Analysis, Methodology, Resources,

Software. MH: Writing – review & editing, Resources. BK: Writing – review & editing, Resources. RG: Writing – review & editing, Funding acquisition, Resources. KD: Writing – review & editing, Resources. IK: Writing – review & editing, Conceptualization, Formal Analysis, Funding acquisition, Supervision, Visualization. SF: Writing – original draft, Writing – review & editing, Conceptualization, Data curation, Formal Analysis, Funding acquisition, Methodology, Project administration, Resources, Supervision, Validation, Visualization.”

The original version of this article has been updated.

## Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.